Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Results
..
All zunsemetinib studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchZunsemetinibZunsemetinib (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis
 

A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19

Gan et al., NCT04481685, NCT04481685, Jun 2025
Source
PDF
All
Studies
Meta
Analysis
https://c19early.org/gan.html
Mortality 0% Improvement Relative Risk Progression -25% Progression b -100% Zunsemetinib  Gan et al.  LATE TREATMENT  DB RCT Is late treatment with zunsemetinib beneficial for COVID-19? Double-blind RCT 20 patients in the USA Trial underpowered to detect differences c19early.org Gan et al., NCT04481685, June 2025 Favorszunsemetinib Favorscontrol 0 0.5 1 1.5 2+
RCT 20 hospitalized patients showing no significant difference in outcomes with ATI-450 (zunsemetinib).
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
risk of death, no change, RR 1.00, p = 1.00, treatment 1 of 10 (10.0%), control 1 of 10 (10.0%).
risk of progression, 25.0% higher, RR 1.25, p = 1.00, treatment 5 of 10 (50.0%), control 4 of 10 (40.0%), death or respiratory failure.
risk of progression, 100% higher, RR 2.00, p = 1.00, treatment 2 of 10 (20.0%), control 1 of 10 (10.0%), advanced respiratory care.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gan et al., 4 Jun 2025, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04481685 (history). Contact: ggan@kumc.edu.
This PaperZunsemetinibAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0